GMO: Value vs Growth Reversals

Johnny HopkinsStock ScreenerLeave a Comment

In their latest Insights, GMO illustrates that the recent reversals from value to growth, and growth back to value, are set to reverse back to value, but not without some drawdowns. Here’s an excerpt from the report:

The Best 3-Year Period For Value vs Growth Also Suffered Some Of Its Worst Drawdowns

The Value vs. Growth reversal, which started in earnest in the late Fall of 2020, generated exciting returns for many of our portfolios through May. In June, however, the reversal did a reversal, with Growth notably beating Value. It was true across the globe but particularly pronounced in the U.S., as the Russell 1000 Value underperformed Growth by 742 bps.

Drawdowns like these are unpleasant, but importantly, from an investor’s mental health perspective, they can be unnerving. The second-guessing starts, questions mount about whether Value’s run was short-lived, and an uncomfortable feeling of “is that it?” arises.

■ Fear not. These profitable trades never happen in a straight line, as history shows.

■ See the first chart above, which shows the historic 3-year reversal of Value vs. Growth from 2000 to 2003. This was the best period in U.S. history. It began for sound reasons, similar to today – the valuation gap between Value and Growth had reached absurd levels by 1999, and mean reversion was inevitable. A long Value/short Growth portfolio would have generated returns of 86% (p.s., it kept being profitable for years afterwards).

■ But it was not a straight line. There were uncomfortable, second-guessing-inducing give-backs along the way. In fact, when we look at the entire 40-year history of the Value vs. Growth relationship (the second chart), 4 of the 10 worst drawdowns ironically occurred during this best 3-year run. If any investors had lost their nerve during any one of these drawdowns, they would have also lost out on the trade of a lifetime.

■ We are not letting a June give-back weaken our resolve, as it was well within expectations. Our thesis remains intact. Value still deserves to win, by a lot. We’ve only just begun.

You can read the original at GMO here:

For all the latest news and podcasts, join our free newsletter here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.